

Index

A

- ACE, 348, 374
- ACL, 367
- ACTN3, 374
- Adaptation. *See* Training adaptation
- Adiponectin, exercise response, 219–220
- Adipose tissue
 - brain effects, 219–220
 - myokine studies
 - metabolism improvement, 263–264
 - subcutaneous white adipose tissue beiging
 - β -aminoisobutyric acid, 262–263
 - FGF-21, 263
 - irisin, 260–262
 - lactate, 263
 - Metrn1, 262
 - myostatin, 262
 - trained adipose tissue regulation of muscle function, 264–265
- ADP, respiratory sensitivity to free ADP, 76
- Aging
 - endurance exercise benefits, 294–295
 - maximal oxygen consumption effects, 28
 - muscle effects
 - atrophy, 192, 194
 - metabolism
 - insulin sensitivity, 196
 - mitochondrial capacity, 196–198
 - overview, 191–192
 - prospects for study, 199
 - regenerative capacity, 198–199
 - sedentary lifestyle impact, 192–193, 195
 - strength, 194–195
 - structure, 194–195
 - performance fatigability, 132–135
- AICAR, 36, 65, 218
- AID, 361
- Akt, 31, 182, 340, 344–345, 347
- ALAS1, 33
- Alcoholism, exercise benefits, 208
- Alzheimer's disease, exercise benefits, 208
- AMPK
 - activation by IL-6, 243
 - AICAR activation, 36, 65
 - calcium effects, 62
 - cognition studies, 218
 - exercise-induced autophagy mediation, 181–182
 - exercise response, 8, 29, 62
 - HDAC as substrate, 365
 - knockout mice, 65
 - PGC-1 α regulation, 79–80
 - substrate discovery, 385
 - training adaptation, 168, 333
- Amyloid- β , 220
- Androgen receptor, 316–317
- ANGPTL4, 239, 243–245, 247
- ANP. *See* Atrial natriuretic peptide
- Anxiety, exercise benefits, 208
- APOBEC, 361
- Argonaute, 348
- Arteries. *See* Vasculature
- ATG6, 184, 186
- ATG7, 181, 184, 186
- ATG13, 178
- ATG101, 178
- ATGL, 63, 66
- ATP
 - exercise
 - metabolism overview, 58–60
 - use, 19
 - muscle fatigue and metabolism, 104–106
 - production pathways, 20–21
- Atrial natriuretic peptide (ANP), 341
- Atrogin-1, 350
- Autism, exercise benefits, 208
- Autophagy
 - exercise benefit mediation
 - disease state modulation, 186
 - glucose regulation, 185–186
 - muscle mass, 184–185
 - overview, 184
 - reactive oxygen species protection, 186
 - exercise-induced autophagy mediators
 - AMPK, 181–182
 - FOXO3, 182–183
 - mTOR, 182
 - p53, 183
 - PGC-1 α , 183–184
 - mechanisms
 - acute exercise-induced autophagy, 180–181
 - overview, 178–179
 - selective autophagy, 178, 180

B

- BAX, 213
- BCL2, 180–181, 184

Index

- BDNF. *See* Brain-derived neurotrophic factor
Beclin-1, 181
 β -Aminoisobutyric acid, 262–263
BNIP3, 180
BNP. *See* Brain natriuretic peptide
Brain-derived neurotrophic factor (BDNF)
 brain response to exercise, 216–217, 246
 epigenetics, 366
 physical activity effects, 29–30, 239
Brain natriuretic peptide (BNP), 341
- C**
- Calcineurin, 331, 350
Calcium flux. *See* Fatigue
Calpain-2, 331
CAMK, 61–62, 331, 333
CAMKII, 78–80, 351, 365
Cardiorespiratory fitness (CRF)
 aging effects, 28
 exercise response, 26–29
Cardiovascular disease. *See also* Vasculature
 burden, 239–240
 exercise
 cardiac response
 overview, 341–343
 pathways, 343–344
 clinical benefits, 340
 rationale for study, 340–341
 risk reduction, 9
CBF. *See* Cerebral blood flow
CCL2, 242, 245
CCN1, 245
CCN2, 245
CD36, 264
CDK8, 326, 330
C/EBP β , 340, 344
Cerebral blood flow (CBF), exercise response, 217
Cervicomedullary-evoked potential (CMEP), 124
CETP, 32
CGV. *See* Cryptic genetic variation
CHI3L1, 245
CITED4, 340
Citrate synthase (CS), 76–77, 161
CK. *See* Creatine kinase
CLC-1, 108
CMEP. *See* Cervicomedullary-evoked potential
CNTF, 250
Cognition, physical activity effects
 brain-derived neurotrophic factor response,
 216–217, 246
 cerebrovascular plasticity, 217–218
 hippocampus effects, 207, 212–215
 long-term potentiation and running, 215
 neurotransmitter response, 215–216
 overview, 29, 207–211
 systemic effects and brain function
 adipose tissue, 219–220
 liver, 220–221
 muscle, 218–219
COL6A, 185
COL1A, 352
Costamere, mechanotransduction, 152
COX, 161
COX1, 33
COX4L1, 363
CPT1, 67
Creatine kinase (CK), 103, 106
CRE. *See* Cardiorespiratory fitness
Cryptic genetic variation (CGV), 43
CS. *See* Citrate synthase
CSA, 164–166
CTGF, 239, 245
CTRP15, 263
CTSB, 246
Ctsb, 218
CXCL3, 244
Cyclin C, 326
CYR61, 239, 245
Cytochrome *b*, 76
Cytochrome *c*, 33
- D**
- DAGC. *See* Dystrophin-associated glycoprotein complex
DCX. *See* Doublecortin
Depression, exercise benefits, 29–30, 209
DGK ζ , 152
DHPR. *See* Dihydropyridine receptor
Diabetes type 2
 complex biology, 31
 epidemiology, 30, 286
 exercise and glucose uptake by muscle, 31
 exerkine mediation, 292–294
 genetic predisposition, 30
 lifestyle interventions, 30–31
 metabolomics studies, 378
 mortality, 286
 proteomics studies, 376
Dihydropyridine receptor (DHPR), 102, 112
DNA methyltransferases (DNMTs), 360–361, 363, 366
DNMTs. *See* DNA methyltransferases
Doublecortin (DCX), 213, 218
Dystrophin-associated glycoprotein complex
 (DAGC), 165
- E**
- Electromyography (EMG), 90, 95–96, 124, 127
Electron transport system (ETS), 15–18
EMG. *See* Electromyography
Energy transfer hypothesis (ETH)

- experimental test, 42–44
- overview, 41–42
- theoretical foundation, 44–49
- Epigenetics
 - epigenomics, 374–375
 - exercise response in nonmuscle tissues, 366
 - mechanisms
 - DNA methylation, 360–361
 - histone modification, 361–363
 - prospects for study, 368–369
 - skeletal muscle response to exercise
 - DNA methylation, 363–364
 - histone modification, 364–365
 - training adaptation
 - induction with epigenetic therapies, 368
 - metabolism and epigenetic interactions, 366
- Epilepsy, exercise benefits, 209
- ERK, 65, 152, 326
- ERRs, 317–318
- ESCRT proteins, 291
- Estrogen receptor, 316
- ETH. *See* Energy transfer hypothesis
- ETS. *See* Electron transport system
- Excitation–contraction coupling, 350–351
- Exercise
 - cardiovascular disease risk reduction, 9
 - components, 5
 - physical activity comparison, 3–5
 - physiological redundancy in response, 7–8
 - systemic and remote responses, 8–9
 - tissue-specific responses, 34–35
- Exercise adaptation. *See* Training adaptation
- Exosome
 - biology and evolution, 288–292
 - exercise benefit mediation, 295–298
- F**
- FABP, 63–65, 67
- FABP3, 363
- FAK, 152
- FAT/CD36, 44, 64–65, 67
- Fatigue
 - acute fatigue and anaerobic metabolism, 103–106
 - age differences, 132–135
 - calcium flux over sarcolemma, 112–113
 - force and position task, 125, 127
 - glycogen depletion, 102, 108–109
 - mitochondrial calcium uptake, 113–114
 - neural mechanisms, 122–125
 - overview
 - mechanisms, 101–103, 122–125
 - performance fatigability, 121–122
 - prospects for study, 114–115, 135
 - reactive oxygen/nitrogen species role, 102–103, 109–112
 - sarcoplasmic reticulum calcium release reduction
 - mechanisms
 - acidosis, 106
 - action potential propagation impairment, 107–108
 - ATP reduction, 107
 - phosphate increase, 106–107
 - overview, 101–103
 - sex differences, 127–132
 - specificity to task demands and population, 125–128
- FATP1, 64–65, 264
- FATP4, 64–65
- Fatty acid oxidation, muscle
 - exercise induction, 63–66
 - overview, 63
- FGF-2, 288
- FGF-21, 247, 263, 292–293
- FIP200, 178
- Flow-mediated dilation (FMD), 274, 276–278
- FMD. *See* Flow-mediated dilation
- FNDC5, 29, 219, 244, 246, 261
- Foxo1, 365
- FOXO3, 182–183
- Fractalkine, 239
- FSTL1, 246
- G**
- GABA receptor, 215
- GABARAP, 180
- Genomics, exercise studies, 374–375
- GFAP, 213
- GLP1, 243
- Glucocorticoid receptor, 317
- GLUT4, 31, 44, 60–63, 259–260, 291–292, 330–333
- GLUT4, 364–365, 367
- Glycogen, depletion in fatigue, 102, 108–109
- GPR56, 150
- GSK4716, 319
- GW501516, 319
- H**
- HAT. *See* Histone acetyltransferase
- HDAC, 331
- HDAC. *See* Histone deacetylase
- HERITAGE family study, 27–28, 263
- HIPK1, 350
- HIPK2, 350
- Hippocampus. *See* Cognition
- Histone acetyltransferase (HAT), 362–364, 367
- Histone deacetylase (HDAC), 221, 362, 364–365, 367–368
- HK2, 367
- HMBOX1, 350

Index

Hormone replacement therapy (HRT), 148
HRT. *See* Hormone replacement therapy
HSL, 63, 66
HSP70, 295
HSP72, 295
Huntington's disease, exercise benefits, 209
Hypertrophy. *See* Muscle hypertrophy

I

IGF-1, 29, 148, 150, 220, 245–246, 288, 292–293, 343
IL-6, 34, 219, 238–239, 242–244, 246–247, 267,
293–295
IL-7, 245
IL-8, 239, 245–246
IL-10, 239, 244
IL-15, 239, 244, 246
Intermediate filament, mechanotransduction,
152–153
Irisin, 32, 219, 260–262
IRS-1, 31

J

JNK, 152

K

KAT. *See* Kynurenine amino transferase
Ketone bodies
HDAC inhibition, 367
neuroprotective effects, 221
Kinin B1 receptor, 32
KLF15, 330
Kynurenine amino transferase (KAT),
physical activity effects, 30

L

Lactate, 263
Lactate dehydrogenase B (LDHB), 32
LBPA, 290
LC3, 178, 180–181, 183–186
LDH, 367
LDHB. *See* Lactate dehydrogenase B
Leptin, 265
LIF, 245, 288
Lipidomics, exercise studies, 378–379
Lipopolysaccharide (LPS), 290
Lipoprotein lipase (LPL), 243
LKB1, 62, 65
Long-term potentiation. *See* Cognition
LPL. *See* Lipoprotein lipase
LPS. *See* Lipopolysaccharide
LXRs, 315–316

M

MABPs. *See* Muscle ankyrin repeat proteins
MAPK, 363
Maximal oxygen consumption (VO_{2max})
aging effects, 28
magnitude of physiological challenges
with exercise, 2
single nucleotide polymorphisms and individual
response, 27
training response, 7, 26
Maximal voluntary contraction (MVC), performance
fatigability, 121, 124, 127, 130–133
Maximum entropy production (MEP), 46, 50
MED1, 328, 332
MED13, 326, 329–332, 334
MED14, 328
MED15, 328
MED23, 328, 334
MED30, 328
Mediator complex
muscle metabolism regulation
exercise-responsive factors, 333–334
glucose, 330
GLUT4 expression regulation, 330–333
lipids, 327–330
prospects for study, 334–335
subunits and metabolic processes, 329
overview, 325–327
MEF2, 78, 330, 333–334, 364–365
MEF2A, 364
MEF2D, 330, 333–334
MEP. *See* Motor-evoked potential
Metabolomics, exercise studies, 378–379
Metrn1, 262, 292–293
MGL, 66
MHC. *See* Myosin heavy chain
MicroRNA
cardiac exercise response
cardiac microRNA types, 344–348
circulating microRNAs, 348–349
exercise phenotype studies
angiogenesis, 352
cardiac fibrosis, 351–352
cardiac hypertrophy, 349–350
cardiomyocyte hyperplasia, 350
excitation–contraction coupling, 350–351
ischemic injury protection, 351
overview, 344
diabetes type 2 expression, 293
exercise response in muscle, 250, 288
transcriptional regulation in muscle
hypertrophy, 150
Mitochondria. *See also* Oxidative phosphorylation
aging effects in muscle, 196–198
bioenergetic efficiency, factors affecting, 21–22

- fatty acid uptake and fat transporter translocation
 - induction by exercise, 67
 - single genes in number determination, 32–33
 - training response in muscle
 - messenger RNS stability, 82
 - molecular basis, 76–79
 - overview, 6, 74–76
 - prospects for study, 82–93
 - signaling, 79–80
 - time course, 80–81
 - MMP9, 296
 - Motor-evoked potential (MEP), 124
 - mTOR, 182, 344, 347
 - mTORC1, 151–152, 163–164, 167–168, 183, 344
 - Multiple sclerosis, exercise benefits, 210
 - MuRF-1, 350
 - Muscle ankyrin repeat proteins (MABPs),
 - mechanotransduction, 153
 - Muscle force
 - common input and force steadiness, 93–95
 - overview, 89–90
 - rate coding
 - adaptations elicited by changes in physical activity, 97
 - adjustment during prolonged activity, 95–97
 - contraction speed, 90–93
 - prospects for study, 97–98
 - shortening and lengthening contractions, 93
 - Muscle hypertrophy
 - heterogeneity of individual response to resistance
 - exercise training, 144–145
 - mechanotransduction
 - costameres, 152
 - intermediate filaments, 152–153
 - muscle ankyrin repeat proteins, 153
 - overview, 151
 - phosphatidic acid, 151–152
 - myokine signaling, 153, 245–246
 - overview, 143–144
 - prospects for study, 153–154
 - ribosome
 - biogenesis, 145–147
 - function, 145
 - satellite cell activity, 147–149
 - transcriptional regulation
 - coregulators, 150–151
 - microRNAs, 150
 - transcriptome profiling, 149–150
 - Musclin, 32
 - MVC. *See* Maximal voluntary contraction
 - MVP1, 245
 - Myokines. *See also specific myokines*
 - adipose tissue studies
 - metabolism improvement, 263–264
 - subcutaneous white adipose tissue beiging
 - β -aminoisobutyric acid, 262–263
 - FGF-21, 263
 - irisin, 260–262
 - lactate, 263
 - Metnrl, 262
 - myostatin, 262
 - endocrine effects, 245–247
 - exercise-regulated myokines
 - microRNAs, 250
 - myometabokines, 249
 - overview, 238–242
 - therapeutic potential, 250
 - exercise systemic effect mediation, 287–288
 - muscle hypertrophy signaling, 153
 - training adaptation role
 - anti-inflammatory effect of exercise, 244–245
 - cancer protection, 246, 294
 - cognition enhancement, 246
 - metabolic pathway regulation, 243–244
 - muscle–bone interactions, 246
 - myogenesis and muscle hypertrophy regulation, 245–246
 - Myonectin, 263–264
 - Myosin heavy chain (MHC)
 - age effects, 132
 - sex differences, 128, 131
 - Myostatin, 243, 262
- N**
- NAMPT, 239, 244
 - NCLX, 113
 - NCoR1, 319
 - NCX1, 351
 - NDUFC2, 364
 - Nestin, 213
 - Neuregulin-1 (NRG-1), 344
 - NFAT, 331, 350
 - Nitric oxide (NO), 62, 273–274
 - NIX, 180
 - NMDA receptor, 215, 217
 - NO. *See* Nitric oxide
 - Nor1, 318, 333
 - Norepinephrine, motor neurons, 91
 - NRF-1, 77–78
 - NRF-2, 77
 - NRG-1. *See* Neuregulin-1
 - NSAIDs, 244
 - Nucleophosmin, 348
 - Nur77, 318, 333
 - NURR1, 331, 333–334
 - Nut77, 44
- O**
- Obesity
 - exerkine mediation, 292–294
 - mortality, 286

Index

- Omics, exercise studies
 epigenomics, 374–375
 genomics, 374–375
 hurdles, 383–385
 lipidomics, 378–379
 metabolomics, 378–379
 network dynamics, 379–382
 overview, 373–374
 protein posttranslational modifications, 377–378
 proteomics, 376–378
 secretome, 376–377
 transcriptomics, 375–376
- Orai1, 112
- Oxidative phosphorylation
 ATP production, 20–21
 bioenergetic efficiency, factors affecting, 21–22
 membrane potential generation of energy charge, 18
 oxygen electronegativity as driving force, 13–14
 reduction potential
 membrane potential generation, 15–18
 overview, 14–15
- P**
- p27, 350
p38 MAPK, 33, 80, 291, 332–333
p53, 161–162, 183
p62, 184, 186
p300, 363
PAC3, 27
Parkinson's disease, exercise benefits, 210
Pax7, 147–148
PDK4, 363, 375
PEPCK, 332
PFK-1, 367
PGC-1 α
 AMPK regulation, 79–80
 autophagy studies, 181, 183–184
 cardiac exercise response and microRNAs, 340–341,
 344, 350
 epigenetics, 363, 365, 375
 exercise response, 8, 29–30, 32–33, 78–79,
 197, 219, 260
 Mediator complex studies, 328, 333
 mitochondrial biogenesis, 293
 muscle hypertrophy role, 150
 nuclear receptor coregulation, 311, 318–319
 splice variants, 262
 training adaptation, 161
PGC-1 β , 33, 318
Phosphatidic acid, mechanotransduction, 151–152
Physical activity
 cardiovascular disease risk reduction, 9
 exercise comparison, 3–5
PI3K, 31, 178, 181–182, 340, 343–345, 347
PINK1, 180
PKC. *See* Protein kinase C
Plethysmography. *See* Vasculature
PLIN1, 66
POLG1 mouse, 295
Posttraumatic stress disorder (PTSD), exercise benefits,
 210
PPARs
 PPAR α , 78, 328, 332
 PPAR δ , 363, 375
 PPAR γ , 78, 327
 PPARGC1A, 364
 training adaptation mediation, 311, 313, 315, 319
PRKAB1, 364
Protein kinase C (PKC), 60, 65
Proteomics, exercise studies, 376–378
PTEN, 344–345
PTSD. *See* Posttraumatic stress disorder
- R**
- Rab, 62
Rab11, 291
Rab27, 291
Rac1, 62
Rate coding. *See* Muscle force
RBP4, 266
Reactive nitrogen species (RNS), muscle fatigue role,
 102–103, 109–112
Reactive oxygen species (ROS)
 autophagy protection, 186
 muscle fatigue role, 102–103, 109–112
Reduction potential
 membrane potential generation, 15–18
 overview, 14–15
Retinoid X receptor (RXR), 310–311, 316
Rev-Erb, 315
Ribosome
 biogenesis, 145–147
 function, 145
RNS. *See* Reactive nitrogen species
RORs, 315
ROS. *See* Reactive oxygen species
RUNX1, 27
RXR. *See* Retinoid X receptor
Ryanodine receptor (RyR), 102, 107, 111–112
RyR. *See* Ryanodine receptor
- S**
- Sarcoplasmic reticulum calcium release. *See* Fatigue
Satellite cell, activity in muscle hypertrophy, 147–149
Schizophrenia, exercise benefits, 211
Secretome, exercise studies, 376–377
SERCA, 101–102, 112, 115, 343, 351
Serotonin
 motor neurons, 91
 receptor, 216

Sex differences, performance fatigability, 127–132
SIRT3, 377
Sirtuin, 365
SMAD2, 52
SNARE, 291
SOD2, 1112
Sox-2, 213
SOX9, 27
SPARC, 246, 294
SR9009, 319
SREBPs, 327
STAT3, 50, 242
STIM1, 103, 112
Stroke, exercise benefits, 211

T

TBC1D1, 31, 62
TET1, 363
TFAM, 77, 79
Tfam, 113
TFEB, 32
TGF- β . *See* Transforming growth factor β
Thyroid hormone receptors, 311
TNF- α , 264, 293
Training adaptation
 concurrent training, 167–168
 endurance training, 160–164
 extracellular matrix role, 247, 249
 genetics, 168–169
 muscle epigenetics
 adaptation induction with epigenetic
 therapies, 368
 metabolism and epigenetic interactions, 366
 myokine roles
 anti-inflammatory effect of exercise, 244–245
 cancer protection, 246
 cognition enhancement, 246
 metabolic pathway regulation, 243–244
 muscle–bone interactions, 246
 myogenesis and muscle hypertrophy regulation,
 245–246
 nuclear receptor mediation
 androgen receptor, 316–317
 classification of receptors, 310–312
 coregulators, 318–319
 ERRs, 317–318
 estrogen receptor, 316
 gain/loss-of-function and muscle
 phenotypes, 314

glucocorticoid receptor, 317
ligands as exercise mimetics, 319
LXRs, 315–316
Nor1, 318
Nur77, 318
PPARs, 311, 313, 315
prospects for study, 319–320
retinoid X receptor, 316
Rev-Erb, 315
RORs, 315
structure of receptors, 310
thyroid hormone receptors, 311
vitamin D receptor, 316
overview, 159–160, 177–178
strength training, 164–167
transforming growth factor β in metabolic
 adaptation, 249
Transcriptomics, exercise studies, 375–376
Transforming growth factor β (TGF- β), 249, 293
Traumatic brain injury, exercise benefits, 211
Triglyceride, exercise-induced breakdown in muscle,
 66–67
TSC2, 344–345

U

UCP1, 21, 261–263, 292
UCP3, 44
ULK1 kinase complex, 178, 181–182

V

Vasculature, exercise effects
 artery function, 273
 overview, 269–270
 plethysmography
 arterial lumen expansion, 271–272
 arterial wall thickness, 272–273
 principles, 270–271
 primary and secondary benefits, 270–271
 prospects for study, 278–280
 structure–function interactions, 278
VDAC, 113
VDR. *See* Vitamin D receptor
VEGF
 exercise induction, 239, 242, 245
 exercise response in brain, 217
Vitamin D receptor (VDR), 316
VO_{2max}. *See* Maximal oxygen consumption
VPS34, 181–182